Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours.

Trial Profile

Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs AZD 4547 (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Lung cancer; Oesophageal cancer
  • Focus Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
  • Acronyms FGFR
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Nov 2015 Planned End Date changed from 31 Dec 2015 to 30 Apr 2017, according to United Kingdom Clinical Research Network record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top